Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer Clinical Impact Jan 20 Written By Frances Benson https://www.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-announces-fda-clearance-1 2022 Frances Benson
Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer Clinical Impact Jan 20 Written By Frances Benson https://www.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-announces-fda-clearance-1 2022 Frances Benson
